Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raymond G Booth

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Pharmacology, Biochemistry, and Behavior|August 12, 2008
Effect of (-)-trans-PAT, a novel 5-HT2C receptor agonist, on intake of palatable food in miceNeil E Rowland, Erica M Crump, Nancy Nguyen, et al.
British Journal of Pharmacology|November 27, 2021
A new class of 5-HT<sub>2A</sub> /5-HT<sub>2C</sub> receptor inverse agonists: Synthesis, molecular modeling, in vitro and in vivo pharmacology of novel 2-aminotetralinsAusten B Casey, Munmun Mukherjee, Ryan P McGlynn, et al.
Bioorganic & Medicinal Chemistry Letters|October 11, 2011
A novel potential therapeutic avenue for autism: design, synthesis and pharmacophore generation of SSRIs with dual actionOla M Ghoneim, Diaa A Ibrahim, Ibrahim M El-Deeb, et al.
European Journal of Pharmacology|October 25, 2011
Drug discovery targeting human 5-HT(2C) receptors: residues S3.36 and Y7.43 impact ligand-binding pocket structure via hydrogen bond formationClinton E Canal, Tania C Cordova-Sintjago, Nancy Y Villa, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 2, 2013
Molecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligandsClinton E Canal, Tania Cordova-Sintjago, Yue Liu, et al.
ACS Pharmacology & Translational Science|June 23, 2020
(<i>S</i>)-5-(2'-Fluorophenyl)-<i>N</i>,<i>N</i>-dimethyl-1,2,3,4-tetrahydronaphthalen-2-amine, a Serotonin Receptor Modulator, Possesses Anticonvulsant, Prosocial, and Anxiolytic-like Properties in an <i>Fmr1</i> Knockout Mouse Model of Fragile X Syndrome and Autism Spectrum DisorderJessica L Armstrong, Austen B Casey, Tanishka S Saraf, et al.
Neuropharmacology|May 14, 2013
Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medicationsDrake Morgan, Krishnakanth Kondabolu, Allison Kuipers, et al.
Pharmacology Research & Perspectives|April 24, 2026
Pharmacologic MRI Brain Imaging Studies of Serotonin 5-HT<sub>1</sub> Receptor Agonists in Awake MiceBrittany M Brems, Erin E Sullivan, Ryan P McGlynn, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 18, 2002
A novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptorsRaymond G Booth, Nader H Moniri, Remko A Bakker, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 25, 2014
A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychosesClinton E Canal, Drake Morgan, Daniel Felsing, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Pharmacology, Biochemistry, and Behavior|August 12, 2008
Effect of (-)-trans-PAT, a novel 5-HT2C receptor agonist, on intake of palatable food in miceNeil E Rowland, Erica M Crump, Nancy Nguyen, et al.
British Journal of Pharmacology|November 27, 2021
A new class of 5-HT<sub>2A</sub> /5-HT<sub>2C</sub> receptor inverse agonists: Synthesis, molecular modeling, in vitro and in vivo pharmacology of novel 2-aminotetralinsAusten B Casey, Munmun Mukherjee, Ryan P McGlynn, et al.
Bioorganic & Medicinal Chemistry Letters|October 11, 2011
A novel potential therapeutic avenue for autism: design, synthesis and pharmacophore generation of SSRIs with dual actionOla M Ghoneim, Diaa A Ibrahim, Ibrahim M El-Deeb, et al.
European Journal of Pharmacology|October 25, 2011
Drug discovery targeting human 5-HT(2C) receptors: residues S3.36 and Y7.43 impact ligand-binding pocket structure via hydrogen bond formationClinton E Canal, Tania C Cordova-Sintjago, Nancy Y Villa, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 2, 2013
Molecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligandsClinton E Canal, Tania Cordova-Sintjago, Yue Liu, et al.
ACS Pharmacology & Translational Science|June 23, 2020
(<i>S</i>)-5-(2'-Fluorophenyl)-<i>N</i>,<i>N</i>-dimethyl-1,2,3,4-tetrahydronaphthalen-2-amine, a Serotonin Receptor Modulator, Possesses Anticonvulsant, Prosocial, and Anxiolytic-like Properties in an <i>Fmr1</i> Knockout Mouse Model of Fragile X Syndrome and Autism Spectrum DisorderJessica L Armstrong, Austen B Casey, Tanishka S Saraf, et al.
Neuropharmacology|May 14, 2013
Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medicationsDrake Morgan, Krishnakanth Kondabolu, Allison Kuipers, et al.
Pharmacology Research & Perspectives|April 24, 2026
Pharmacologic MRI Brain Imaging Studies of Serotonin 5-HT<sub>1</sub> Receptor Agonists in Awake MiceBrittany M Brems, Erin E Sullivan, Ryan P McGlynn, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 18, 2002
A novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptorsRaymond G Booth, Nader H Moniri, Remko A Bakker, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 25, 2014
A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychosesClinton E Canal, Drake Morgan, Daniel Felsing, et al.
Pageof 4